A citation-based method for searching scientific literature

Chantal Mathieu, Laura Van Den Mooter, Bert Eeckhout.  2019
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
875
100

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
227
100

Clinical features and therapeutic perspectives on hypertension in diabetics.
Shigehiro Katayama, Masako Hatano, Masashi Issiki. Hypertens. Res. 2018
7
100

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
282
100

Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus.
K Nørgaard, B Feldt-Rasmussen, K Borch-Johnsen, H Saelan, T Deckert. Diabetologia 1990
70
100

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press. 2016
43
100

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel,[...]. Diabetologia 2015
56
100

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, Hyo Jin Maeng, Dong Hwa Lee, Kyoung Min Kim, Sung Hee Choi, Hak Chul Jang, Hye Seung Lee, Kyong Soo Park,[...]. Diabetologia 2017
49
100


Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
255
100


Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
180
100

The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Alvaro Garcia-Ropero, Juan J Badimon, Carlos G Santos-Gallego. Expert Opin Drug Metab Toxicol 2018
20
100


Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
L Thomas, R Grempler, M Eckhardt, F Himmelsbach, A Sauer, T Klein, P Eickelmann, M Mark. Diabetes Obes Metab 2012
37
100

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Seok Joon Shin, Sungjin Chung, Soo Jung Kim, Eun-Mi Lee, Young-Hye Yoo, Ji-Won Kim, Yu-Bae Ahn, Eun-Sook Kim, Sung-Dae Moon, Myung-Jun Kim,[...]. PLoS ONE 2016
43
100

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
100

Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension.
Robert J Huggett, Eleanor M Scott, Stephen G Gilbey, John B Stoker, Alan F Mackintosh, David A S G Mary. Circulation 2003
162
100

Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.
Akiko Sarashina, Kazuki Koiwai, Leo J Seman, Norio Yamamura, Atsushi Taniguchi, Takahiro Negishi, Shogo Sesoko, Hans J Woerle, Klaus A Dugi. Drug Metab. Pharmacokinet. 2013
53
100


Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi. BMC Pharmacol Toxicol 2017
26
100


Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
216
100

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat. Med. 2015
295
100

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
Tim Heise, Leo Seman, Sreeraj Macha, Peter Jones, Alexandra Marquart, Sabine Pinnetti, Hans J Woerle, Klaus Dugi.  2013
68
100

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. Clin Pharmacol Drug Dev 2013
66
100

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
Sreeraj Macha, Arvid Jungnik, Kathrin Hohl, Dagmar Hobson, Afshin Salsali, Hans J Woerle. Int J Clin Pharmacol Ther 2013
17
100


Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
William L Baker, Leo F Buckley, Michael S Kelly, John D Bucheit, Eric D Parod, Roy Brown, Salvatore Carbone, Antonio Abbate, Dave L Dixon. J Am Heart Assoc 2017
49
100

Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.
L M Ruilope, A Salvetti, K Jamerson, L Hansson, I Warnold, H Wedel, A Zanchetti. J. Am. Soc. Nephrol. 2001
289
100

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N. Engl. J. Med. 2016
100

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
72
100

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int. 2018
54
100


Hypertension management in patients with diabetes: the need for more aggressive therapy.
Dan R Berlowitz, Arlene S Ash, Elaine C Hickey, Mark Glickman, Robert Friedman, Boris Kader. Diabetes Care 2003
99
100

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr. Rev. 2011
231
100

Antihypertensive drugs.
Stéphane Laurent. Pharmacol. Res. 2017
31
100

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
181
100



British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.
Bryan Williams, Neil R Poulter, Morris J Brown, Mark Davis, Gordon T McInnes, John F Potter, Peter S Sever, Simon McG Thom. BMJ 2004
472
100


Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
127
100

Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study.
F Collado-Mesa, H M Colhoun, L K Stevens, J Boavida, J B Ferriss, B Karamanos, P Kempler, G Michel, G Roglic, J H Fuller. Diabet. Med. 1999
33
100

Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population.
David M Maahs, Gregory L Kinney, Paul Wadwa, Janet K Snell-Bergeon, Dana Dabelea, John Hokanson, James Ehrlich, Satish Garg, Robert H Eckel, Marian J Rewers. Diabetes Care 2005
86
100


Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Giuseppe Mancia, Christopher P Cannon, Ilkka Tikkanen, Cordula Zeller, Ludwin Ley, Hans J Woerle, Uli C Broedl, Odd Erik Johansen. Hypertension 2016
41
100

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
125
100

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma, Ankit Garg, Andrew T Yan, Anup K Gupta, Mohammed Al-Omran, Andre Sabongui, Hwee Teoh, C David Mazer, Kim A Connelly. Diabetes Care 2016
80
100

ABC of hypertension: The pathophysiology of hypertension.
G Beevers, G Y Lip, E O'Brien. BMJ 2001
133
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.